Pomerantz LLP Launches Investigation into Beam Therapeutics

The inquiry centers on the company’s September 8, 2026, announcement concerning Phase 1/2 trial data for BEAM-302, a treatment for alpha-1 antitrypsin deficiency. While Beam Therapeutics reported that the single-dose treatment maintained an acceptable safety profile, the disclosure revealed transient Grade 1 elevations in alanine transaminase and aspartate aminotransferase levels among participants. Investors reacted sharply to the news, driving the company’s stock price down by 9.54%, or $2.83 per share, to close at $26.83.

Pomerantz LLP, a firm specializing in securities class litigation, is now soliciting contact from shareholders affected by the recent price volatility. The firm, which maintains an international presence across six global cities, aims to determine if the clinical trial reporting constitutes a breach of fiduciary duty or corporate misconduct.